DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/0bf1eb/medical_nanotechno) has announced the addition of the "Medical Nanotechnology Market Guide 2012" report to their offering.
Nanotechnology is widely considered to be one of the most promising technologies of the 21st century. Recent advances in nanotechnology-related drug delivery, diagnosis and drug development are beginning to alter the landscape of medicine.
While nanomedicine potentially offers promising new value propositions and revenue streams, in diagnostics for example, it could also completely displace certain classes of drugs such as current chemotherapy agents with novel nanoparticle reformulations.
This report examines the roles nanotechnology plays in the pharmaceutical industry. It also provides contact information for 34 Venture Capital and Private Equity Investors that are invested in nano start-up companies.
The new field of nanomedicine has major potential and is already being used as the basis for new, more effective drug delivery systems and is in early stage development as scaffolding in nerve regeneration research.
Current applications of medical nanotechnology include: Appetite Control, Bone Replacement, Cancer, Chemical Substitute, Cholesterol , Diagnostic Tests, Drug Development, Hormone Therapy, Imaging, and Immunosuppressant.
Nanotechnology is moving from being used in passive structures to active structures, through more targeted drug therapies or "smart drugs." These new drug therapies have been shown to cause fewer side effects and be more effective than traditional therapies.
In the future, nanotechnology will aid in the formation of molecular systems that may be strikingly similar to living systems. These molecular structures could be the basis for the regeneration or replacement of body parts that are currently lost to infection, accident, or disease.
These predictions have great significance not only in encouraging nanotechnology research and development but also in determining a means of oversight. The number of products approaching the FDA approval and review process is likely to grow as new nanotechnology medical applications are developed.
Companies Mentioned:
- Ablynx
- Access Pharmaceuticals, Inc
- Acusphere Inc
- CytImmune
- Nucryst
- Nanobiotix
- Oxonica
- Nanotherapeutics
- NanoBio
- BioDelivery Sciences
- NanoBioMagnetics
For more information visit http://www.researchandmarkets.com/research/0bf1eb/medical_nanotechno
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
There are no comments yet